The signaling pathways involved in the anticonvulsive effects of the adenosine A1 receptor by Spanoghe, Jeroen et al.
 International Journal of 
Molecular Sciences
Review
The Signaling Pathways Involved in the Anticonvulsive Effects
of the Adenosine A1 Receptor




Citation: Spanoghe, J.; Larsen, L.E.;
Craey, E.; Manzella, S.; Van Dycke, A.;
Boon, P.; Raedt, R. The Signaling
Pathways Involved in the
Anticonvulsive Effects of the
Adenosine A1 Receptor. Int. J. Mol.
Sci. 2021, 22, 320. https://doi.org/
10.3390/ijms22010320
Received: 14 November 2020
Accepted: 27 December 2020
Published: 30 December 2020
Publisher’s Note: MDPI stays neu-
tral with regard to jurisdictional clai-
ms in published maps and institutio-
nal affiliations.
Copyright: © 2020 by the authors. Li-
censee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and con-
ditions of the Creative Commons At-
tribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 4Brain, Department of Head and Skin, Ghent University, 9000 Ghent, Belgium;
Jeroen.Spanoghe@UGent.be (J.S.); LarsEmil.Larsen@UGent.be (L.E.L.); Erine.Craey@UGent.be (E.C.);
Simona.Manzella@UGent.be (S.M.); Paul.Boon@UZGent.be (P.B.)
2 Department of Neurology, General Hospital Sint-Jan Bruges, 8000 Bruges, Belgium;
Annelies.VanDycke@azsintjan.be
* Correspondence: Robrecht.Raedt@UGent.be
Abstract: Adenosine acts as an endogenous anticonvulsant and seizure terminator in the brain.
Many of its anticonvulsive effects are mediated through the activation of the adenosine A1 receptor,
a G protein-coupled receptor with a wide array of targets. Activating A1 receptors is an effective
approach to suppress seizures. This review gives an overview of the neuronal targets of the adenosine
A1 receptor focusing in particular on signaling pathways resulting in neuronal inhibition. These
include direct interactions of G protein subunits, the adenyl cyclase pathway and the phospholipase
C pathway, which all mediate neuronal hyperpolarization and suppression of synaptic transmission.
Additionally, the contribution of the guanyl cyclase and mitogen-activated protein kinase cascades to
the seizure-suppressing effects of A1 receptor activation are discussed. This review ends with the
cautionary note that chronic activation of the A1 receptor might have detrimental effects, which will
need to be avoided when pursuing A1 receptor-based epilepsy therapies.
Keywords: adenosine; adenosine A1 receptor; epilepsy; signaling pathways; neuromodulation;
inhibition
1. Introduction
Epilepsy is a chronic brain disease ranking among the most common neurological
disorders with an estimated prevalence of around 1% worldwide [1,2]. First-line treatment
consists of pharmacotherapy with anti-epileptic drugs. Despite the development and
approval of more than 20 new drugs over the past few decades, about one third of all
epilepsy patients cannot be effectively treated this way [3,4]. This significant proportion
of patients suffering from drug-resistant epilepsy has been an important drive for the
search for new and better epilepsy treatments. In this regard, a lot of research has focused
on the role of adenosine in epilepsy, owing to its ability to act as an endogenous seizure
terminator and its potent anticonvulsive effects [5–7]. A great deal of studies have examined
the mechanisms behind the anti-epileptic effects of adenosine and demonstrated that
adenosine or adenosine analogues are effective in suppressing epileptic seizures, and this
mainly through activation of adenosine A1 receptors. Several excellent reviews have been
published in recent years describing the current knowledge on the role of adenosine in
epilepsy and its therapeutic potential (see references [8–10]). The aim of this review is to
specifically focus on the inhibitory A1 receptors and their downstream signaling pathways,
giving an overview of the consequential neuronal effects and how these effects contribute
to the seizure suppressing role of adenosine.
2. Adenosine in the Central Nervous System
Adenosine is a purine ribonucleoside fulfilling an important role in many physiologi-
cal processes [11]. It has a general homeostatic role as modulator of cellular metabolism,
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but in the central nervous system (CNS) it also distinctively functions as a neuromodula-
tor [12]. Adenosine is involved in various neural processes, including the regulation of
sleep, arousal, nociception and respiration [13–16].
Adenosine is constitutively present at low concentrations in the brain, with basal ex-
tracellular adenosine levels kept in the range of 50–200 nM through enzymatic control [17].
The main source of adenosine in the brain is the intra- and extracellular breakdown of
adenine nucleotides by 5′-nucleotidases (Figure 1). Adenine nucleotides released in the
extracellular space, such as adenosine triphosphate (ATP) or adenosine monophosphate
(AMP), are rapidly converted to adenosine [18]. Intracellularly, the formation of adenosine
is linked to the energy consumption of the cell. An increase in cellular workload and in
degradation of cytoplasmic ATP leads to increased formation of adenosine, with small
intracellular changes in the concentration of ATP resulting in substantial changes in adeno-
sine concentrations relative to its basal levels [12,19]. Adenosine formed intracellularly
then exits the cell via equilibrative nucleoside transporters (ENTs), which allow for bidirec-
tional passive transport of adenosine according to the concentration gradient. This way,
extracellular adenosine concentration is mainly regulated via two intracellular enzymes:
adenosine deaminase (ADA), which catabolizes adenosine to inosine, and adenosine kinase
(ADK), which phosphorylates it to AMP [17,20]. Under physiological conditions, ADK is
the main regulator of adenosine concentrations, but when concentrations increase in case
of energy imbalance ADA exerts a more important role [21].
Figure 1. Adenosine metabolism in the brain: intra-(IC) and extracellular (EC) catabolization of
adenine nucleotides (ATP, ADP, AMP) by nucleotidases (NT) leads to formation of adenosine.
Intracellularly, adenosine deaminase (ADA) breaks down adenosine to inosine and adenosine kinase
(ADK) phosphorylates adenosine to AMP. Bidirectional transport of adenosine via equilibrative
nucleoside transporters (ENT) equalizes the IC and EC adenosine concentrations.
Extracellular adenosine exerts its modulatory effects via binding to G protein-coupled
receptors (GPCRs), of which four subtypes have been characterized: A1, A2A, A2B and A3.
These subtypes possess different affinities for adenosine and couple to specific G proteins.
The adenosine A1 receptor (A1R) couples to Gi and Go proteins, the adenosine A2A receptor
(A2AR) couples to Gs and Golf proteins, the adenosine A2B receptor (A2BR) couples to Gs
and Gq proteins and the adenosine A3 receptor (A3R) couples to Gi and Gq proteins [20].
The A1 and A2A subtypes are high affinity receptors, with the A1R possessing the highest
affinity for adenosine. They are the most abundantly expressed adenosine receptors in the
CNS, while the A2BR and A3R have much lower affinities and are only expressed there in
comparatively small numbers [13]. Highest CNS expression levels of the A1R are found
in the neocortex, hippocampus, thalamus, cerebellum and spinal cord. The A2ARs on the
other hand are predominantly expressed in the striatum [22].
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3. Role of Adenosine in Epilepsy
Epilepsy is characterized by the generation of recurrent, unprovoked seizures [23].
These epileptic seizures are disruptions of neurological function caused by excessive or
hypersynchronous neuronal activity and can be seen as the consequence of an imbalance
between excitation and inhibition in the brain [24]. Excessive excitation and/or deficient in-
hibition leads to uncontrolled firing of neurons, which causes great metabolic stress during
seizures. Consequently, adenosine levels rise and, because of its homeostatic role, adeno-
sine responds as an endogenous anticonvulsant to counter this neuronal hyperactivity.
This link between adenosine and epilepsy was initially discovered 40 years ago.
Studies focused on the involvement of adenosine in the regulation of cerebral blood
flow showed an increase in adenosine levels during bicuculline-induced seizures [25,26].
Around the same time, the anticonvulsive properties of adenosine were demonstrated
for the first time in vitro, in a hippocampal slice model [5], which triggered a wave of
studies that confirmed the anticonvulsive effects of adenosine or adenosine analogues both
in vitro [27] and in vivo [6,28,29]. The increase in adenosine concentrations during seizures
was later also demonstrated in human patients with epilepsy using microdialysis [7]. Here,
adenosine was found to reach levels high enough to suppress epileptiform activity in vitro
and its concentrations remained elevated for the entire postictal period. These findings
further supported the hypothesis that adenosine acts as an endogenous anticonvulsant and
seizure terminator.
Soon after the first demonstration of the anticonvulsive properties of adenosine, the
importance of A1Rs in mediating these effects was suggested [28]. In vitro electrophysi-
ological studies showed that A1Rs were responsible for the inhibitory neuromodulatory
effects of adenosine [30,31]. In various in vivo studies A1R agonists suppressed electrically
or chemically induced seizures while A1R antagonists conversely aggravated seizure activ-
ity [32–36]. Furthermore, the potency of adenosine analogues as anticonvulsants was found
to be positively correlated with their affinity for the A1R [37]. Besides studies demonstrat-
ing the anticonvulsant effects of exogenous activation of A1R, experiments with transgenic
A1R-knock out animals delivered proof of the importance of endogenous adenosine acting
on A1Rs. Deletion of A1Rs in mice leads to spontaneous seizures, increased spreading of
induced seizures, aggravated seizure-induced brain damage and even the development of
lethal status epilepticus [38–40].
Changes in the expression levels of A1Rs after seizures also further underline their
relevance in relation to seizures and epilepsy. In acute seizure models, there is a clear
upregulation of A1R expression in a matter of hours after the induction of seizures [41–43].
This shows that in an initial response to seizures, there is a potentiation of the anticonvulsive
effects of the adenosinergic system by increasing the amount of A1Rs. However, the
long-term modifications in chronic epilepsy are less straightforward. Multiple studies
present contradictory results regarding changes in A1R expression in chronic epilepsy
(Table 1). In temporal cortex biopsies from temporal lobe epilepsy (TLE) patients, both
increases and decreases in A1R density have been reported [44,45]. In the latter case,
however, biopsies of epileptic cortex were compared to control tissue of post-mortem
human brains [45]. Initial studies in chronic seizure models indicated that brain structures
affected by seizures displayed a decreased expression of A1Rs [46–48]. However, later
studies also found increases in A1Rs and A1R mRNA in the epileptic brains of kindled
animals [49,50]. The exact reason for these conflicting results remains unclear, they could
be in part due to methodological differences between the studies. Nevertheless, it is
evident that changes in the expression of A1Rs must play a role in epilepsy. An increase
in A1Rs in case of chronic seizures could, similarly to the response to acute seizures,
indicate the presence of an endogenous adaptive mechanism to limit the hyperexcitability
of epileptic networks. On the other hand, reports of the loss of A1Rs after repeated seizures
have led to the hypothesis that, together with maladaptive changes in the metabolism of
adenosine (e.g., the overexpression of astroglial ADK [51]), this impairment of the inhibitory
modulatory adenosine system is an important aspect in the development and progression
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of chronic epilepsy. Despite a possible decrease in A1R expression levels, administration
of A1R agonists in chronic epilepsy models is still able to produce robust anticonvulsive
effects [36,52]. It is thus very clear that inhibitory A1Rs are largely responsible for the
contribution of adenosine in epilepsy. For this reason, the following sections of this review
will focus on this adenosine receptor subtype.
Table 1. Changes in expression levels of A1Rs in chronic epilepsy.
Observations in TLE Patients




- Excised epileptic temporal lobe tissue
refractory TLE patients (n = 5) Excised control
temporal lobe tissue brain tumor patients (n = 6)
- Autoradiographic labeling of A1R with [3H]CHA





- Excised epileptic temporal lobe tissue
refractory TLE patients (n = 15)
- Post-mortem control temporal lobe tissue from
non-epileptic subjects (n = 9)
- Autoradiographic labeling of A1R with [3H]CHA
- 70% decrease in A1R binding density
[45]
Observations in chronic epilepsy models
Change Animal model Timeframe Detection method + results Ref.
Decreased A1R expression
in CA2/CA3 regions of
epileptic rats
- Wistar rats





- Immunohistochemical labeling with A1R antibody
- Near 100% loss of A1R immunoreactivity
- Decrease in A1R immunoreactivity on stimulated
but not on contralateral side of kindled animals
[46]
Decreased A1R expression
in CA1/CA3 regions of
epileptic rats
- S-D rats
- KA i.p. treatment
30 days after
treatment
- Autoradiographic labeling of A1R with [3H]CHA
- 70% decrease in A1R density in CA1, 40% decrease
in CA3
- related to neuronal degradation
[47]
Decreased A1R expression






- Autoradiographic labeling of A1R with [3H]R-PIA
- Immunohistochemical labeling with A1R antibody





- PTZ kindling (i.p.)
1–4 weeks after
treatment
- Autoradiographic labeling of A1R with [3H]CHA
- >20% increase in A1R binding
[49]
Increased A1R expression
in medial entorhinal cortex







- Immunohistochemical labeling with A1R antibody
- 378% increase in A1R mRNA
- 60% increase in A1R immunoreactivity
[50]
4. A1R Structure, Activation and Expression
The A1R, together with the other adenosine receptors, belongs to the GPCR superfam-
ily and is further classified into the α subfamily of the rhodopsins (formerly called “class A”
of the GPCR superfamily) [53]. It is a glycoprotein with a molecular mass of ~36 kDa and,
like all GPCRs, consists of 7 transmembrane α-helices, 3 extracellular and 3 intracellular
loops, an extracellular N-terminus and an intracellular C-terminus [53,54]. The first four
transmembrane domains of the A1R, (from the N-terminus to the end of the second extracel-
lular loop) have been shown to be important for ligand binding and conferring specificity
for A1-selective agonists/antagonists [55]. More recently, the determination of the crystal
structure of the A1R in its inactive state has confirmed that conformational differences in
these regions, especially the distinct conformation of the second extracellular loop, could
underlie the selectivity of ligands for the A1 subtype [56]. Binding of an agonist to the A1R
induces structural changes leading to receptor activation. The overall activation process is
similar for all GPCRs and involves the relative rearrangement of transmembrane helices. A
key transition during activation is the outward movement of the intracellular part of the
transmembrane helix 6 (Figure 2), which has been observed in multiple GPCRs including
the adenosine-bound A1R [57]. This opens up the cytosolic side of the receptor and enables
interaction with G proteins, resulting in a ternary complex between agonist, receptor and
G protein. Experiments with fusion proteins of the A1R and G protein subunits have
indicated that receptor activation is the rate-limiting step in this ternary complex formation,
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rather than the interaction between the activated receptor and the G protein [58]. The
kinetics of this activation process have been studied by looking at conformational changes
with fluorescence resonance energy transfer (FRET) sensors. In these studies, receptor
activation times were indirectly measured in various GPCRs and were found to be in the
range of 30–50 ms [59].
Figure 2. The G protein activation cycle: (1) in its inactive state, the α-subunit (Gα) binds guanosine
diphosphate (GDP) and forms a heterotrimeric G protein complex with the β- and γ-subunits
(Gβγ). (2) Binding of an agonist to a G-protein coupled receptor (GPCR) induces conformational
changes. The outward movement of transmembrane helix 6 enables interaction of the GPCR with the
heterotrimeric G proteins, catalyzing the exchange of GDP for GTP. (3) Gα and Gβγ then dissociate
and interact with effectors. (4) Gα-induced hydrolyzation of GTP to GDP causes the G protein
subunits to associate and return to their inactive state.
The gene coding for the human A1R is located on the long arm of chromosome 1 and
contains two separate promotors; A and B [60,61]. This results in two distinct transcripts
of the A1R gene: transcript α produced by promoter A and transcript β produced by
promoter B. Transcript β is found in all tissues expressing A1Rs while transcript α is only
seen in tissues with high levels of A1R expression, such as the brain, testis and kidney [61].
This is due to multiple AUG codons in the 5′-untranslated region of transcript β which
hinder protein expression at the post-transcriptional level [62]. In the CNS, A1Rs are
most abundant in neurons, but A1Rs are also expressed by astrocytes, microglia and
oligodendrocytes [63]. Receptor distribution varies per region, with the highest densities
of A1Rs being found in the hippocampus [64]. The subcellular localization has been
investigated in rat hippocampal neurons, where A1Rs are present extrasynaptically on
the membrane of cell bodies, axons and dendrites and synaptically in the active zone of
presynaptic terminals and at the postsynaptic density [65–68].
5. A1R Signaling
5.1. Coupling to G Proteins
G proteins are heterotrimeric complexes composed of a nucleotide-binding α-subunit
(Gα) and a dimer containing the β- and γ-subunits (Gβγ). In its inactive state Gα is
bound to guanosine diphosphate (GDP) and forms a stable complex with Gβγ. Activated
GPCRs can interact with inactive G proteins and catalyze the release of GDP from the
Gα subunit, which is rapidly replaced by guanosine triphosphate (GTP). This induces the
dissociation of the heterotrimeric complex from the GPCR and a separation of the subunits.
The GTP-bound Gα subunit, now in its active state, and the Gβγ subunit are then both
free to interact with downstream effectors. Gα, which possesses intrinsic GTPase activity,
hydrolyzes the bound GTP to GDP, terminating the signal. Then, Gβγ can be recruited
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and the inactive heterotrimeric complex is formed again (Figure 2) [69]. According to
this traditional model of G protein signaling, there is a physical dissociation of Gα and
Gβγ upon activation. Some studies point at a rearrangement rather than a dissociation
of Gα and Gβγ subunits upon receptor activation. For example, Bünemann et al. found
an increase in FRET signal upon receptor activation in living cells instead of the expected
decrease if Gα and Gβγ subunits would dissociate [70].
G proteins are usually grouped into four main classes based on similarities between
the Gα units: Gs, Gi/o, Gq/11 and G12/13 [71]. These classes distinctively affect specific
second messenger pathways. A1Rs couple to several members of the pertussis toxin (PTX)
sensitive Gi/o group, namely Gi1, Gi2, Gi3 and Go1 [72,73]. Gi proteins are named in
accordance with their inhibitory effect on adenyl cyclase. The Go protein was discovered
later, during the purification of Gi proteins, and was named as the ‘other’ GTP-binding
protein. It is now known that Go is 5 to 10 times more abundant than other Gi proteins
and is the most abundant G protein in the CNS [74]. It is worth noting that A1Rs can also
interact with other G proteins. In Chinese hamster ovary (CHO) cells, the A1R can also
activate GS and Gq proteins depending on the agonist used [75]. It has been suggested that
agonist-specific conformations of the receptor lead to differential activation of Gi/o, Gs or
Gq. Yet, coupling to Gi/o proteins remains the most prominent way of A1R signaling and
the neuronal inhibitory effects of A1R activation are thus traditionally viewed to be mainly
mediated by this group of G proteins.
5.2. Adenyl Cyclase and Phospholipase C
When A1Rs are being discussed in literature, their effects are mostly commonly
attributed to downstream activation of two major signaling pathways: the adenyl cyclase
(AC) pathway and the phospholipase C (PLC) pathway [11,22,76]. The former is the most
prominent and well-known A1R–dependent signaling pathway: A1R activation leads to
inhibition of AC and as a result less ATP is converted to the second messenger cyclic
AMP (cAMP). Cyclic AMP activates protein kinase A (PKA) which then phosphorylates
numerous proteins, including several transcription factors such as the well-studied cAMP
response binding protein (CREB) [77]. The inhibition of AC by Gi/o-coupled receptors is
mediated via Gαi subunits, but not by the α- subunit of the more abundant Go proteins [74]:
purified GTP-bound Gαi1, Gαi2 and Gαi3 units can suppress AC activity, while Gαo
cannot [78]. This was also confirmed in a later experiment with mutationally activated Gα
units, where Gαi1, Gαi2, Gαi3 but not Gαo inhibited cAMP accumulation [79].
Regulation of the PLC pathway by A1Rs is less straightforward as there are both
reports of A1R-dependent stimulation and inhibition of PLC activity. Phospholipase C
enzymatically cleaves the membrane phospholipid phosphatidylinositol 4,5-bisphosphate
(PIP2) into diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3), which both function
as important second messengers [80,81]. Diacylglycerol activates protein kinase C (PKC),
which phosphorylates a variety of intracellular proteins, while IP3 binds to IP3-gated
calcium channels on the membrane of the endoplasmic reticulum. PIP2 regulates the
activity of several membrane-bound ion channels, mostly increasing their activity [82]. By
hydrolyzing PIP2, PLC thus regulates those channels in the opposite way.
Most often, it is stated that A1Rs activate PLC-dependent signaling [11,22,76]. Studies
in a smooth muscle cell line (DDT1 MF2) showed increased formation of IP3 and DAG
upon administration of a selective A1R agonist, increasing PKC activity and mobilizing
intracellularly stored Ca2+ [83,84]. This positive modulation was confirmed in CHO cells
transfected with the rat or human A1R gene [85,86]. These cells showed an increase in
IP3 formation and Ca2+ mobilization in response to A1R agonists. When A1R-expressing
cells are transfected with a scavenger of Gβγ the A1R induced increase in IP3 formation
is abolished [87]. This is in line with earlier studies showing that purified Gβγ units
directly regulate the activity of PLC [88,89]. However, studies investigating the inhibitory
effects of adenosine with CNS-derived tissue found conflicting results. In accordance with
the enhancing effect on PLC activity seen in non-neuronal preparations, A1R stimulation
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in guinea-pig cerebral cortical slices [90] and rat striatal slices [91] further augmented
histamine-induced IP3 accumulation. Yet, in mouse cerebral cortical slices [92] stimula-
tion of A1Rs resulted in decreased histamine-induced IP3 formation. Additionally, in rat
hippocampal slices selective A1R agonists inhibit PLC basal activity through Gi/o pro-
teins [93,94]. As will be discussed in the next sections, either an increase or decrease in PLC
activity could mediate the inhibitory effects of A1R activation.
5.3. Main Inhibitory Effects
The inhibitory mechanisms through which A1Rs exert their anticonvulsive effect occur
in two major ways: by decreasing the excitability of neurons via hyperpolarization and
through suppressing neurotransmission.
5.3.1. Hyperpolarization
Hyperpolarization of neurons is considered one of the most important mechanisms
contributing to A1R-mediated seizure suppression. Stimulation of A1Rs opens postsynaptic
K+ channels resulting in potassium efflux. This increased K+ conductance decreases the
membrane potential and antagonizes membrane depolarization, rendering neurons less
excitable. This adenosine-induced hyperpolarization was already demonstrated in 1982
through intracellular recordings in rat hippocampal slices. The investigators already sug-
gested an increase in K+ conductance as mechanism [95]. This suggestion was confirmed
by several studies a few years later: under voltage clamp, adenosine elicited outward
K+ currents in mouse striatal neurons and in rat CA1 hippocampal neurons [96,97]. The
observed hyperpolarization, between 2 and 10 mV in amplitude, was relatively slow as the
outward K+ current only peaked 1–2 s after adenosine application [96].
Explained in more in detail in the following sections, follow-up studies identified
the specific channels responsible for this A1R-mediated outward K+ current such as G
protein-coupled inwardly rectifying K+ (GIRK) channels and ATP-sensitive K+ (KATP)
channels (Figure 3). Moreover, small conductance Ca2+-activated K+ channels and two-
pore domain K+ channels were reported to be activated by A1R signaling, respectively, in
retinal ganglion cells [98] and mitral cells [99].
GIRK Channels
Soon after discovering the adenosine-activated K+ current in striatal neurons, Trussel
and colleagues reported this current to be dependent on PTX-sensitive Gi/o proteins and
GTP [100]. This indicated that adenosine can also activate GIRK channels in neurons,
as was already demonstrated for heart muscle cells. In rat CA3 hippocampal neurons
adenosine-induced activation of GIRK currents could be blocked with A1R antagonists,
while A1R agonists mimicked the hyperpolarizing effect of adenosine, indicating that
A1Rs are mediating adenosine-induced activation of GIRK channels [101]. GIRK channels
(also known as Kir3 channels) belong to a large family of inwardly rectifying K+ channels.
The term ‘inward rectification’ refers to the property of these channels to conduct larger
inward currents at membrane voltages negative to the K+ equilibrium potential (EK) than
outward currents at voltages positive to this potential. Since the membrane potential of
neurons under physiological conditions is positive to EK, the opening of Kir channels
results in a small outward K+ current [102]. Four different GIRK subunits (GIRK1-4, or
Kir3.1-4) are expressed in mammals and assemble into homo- or heterotetramers to form
functional GIRK channels. In the brain, the subunits GIRK1-3 are the most common [103].
A wealth of research indicates that direct binding of Gβγ is mainly responsible for opening
of GIRK channels upon G-protein activation [102]. For instance, in Xenopus oocytes only
co-expression of GIRK with Gβγ units, but not with Gα, resulted in sustained GIRK
channel activity [104]. As well, binding sites for Gβγ could be identified in the N- and C-
terminal domains of GIRK1 subunits that are important in GIRK channel activation [105].
However, the Gα subunit plays an important regulatory role. Binding of Gαi/o affects
receptor specificity so that only Gβγ dimers derived from Gi/o proteins can activate GIRK
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channels [106]. It also controls gating of GIRK channels, with Gα keeping the basal channel
activity low [107,108]. Hence, A1R stimulation leads to the activation of GIRK channels in
neurons via direct binding of both G protein subunits. Additionally, the PLC pathway is
involved in regulation of GIRK channel activity. PLC reduces GIRK channel activity by
depleting PIP2, which acts as a positive modulator of GIRK channels [103], and by inducing
PKC-mediated phosphorylation of GIRK channels [109,110]. A1R activation in neurons
can reduce PLC activity (see higher) and its inhibitory effects on GIRK channel function,
resulting in a net inhibition of neurons.
Figure 3. Schematic representation of the signaling pathways involved in increased K+ permeability
and hyperpolarizing effects of A1R activation. A1Rs activate G protein-coupled inwardly rectifying
K+ (GIRK) channels directly via the G protein subunits (Gα and Gβγ) or indirectly by inhibiting PLC
activity. A1Rs increase ATP-sensitive K+ (KATP) channel activity by inhibiting the AC/cAMP pathway
or by both stimulating (via increased PKC) or inhibiting (via increased PIP2) the PLC pathway. A1R-
induced IP3 stimulation activates small conductance Ca2+-activated K+ (SK) channels by increasing
intracellular Ca2+ concentration. The pathway underlying activation of two-pore domain K+ (K2P)
channels is unknown and therefore not presented here. AC: adenyl cyclase; cAMP: cyclic adenosine
monophosphate; PKA: protein kinase A; PLC: phospholipase C; PIP2: phosphatidylinositol 4,5-
bisphosphate; IP3: inositol 1,4,5-trisphosphate; DAG: diacylglycerol; PKC: phosphokinase C.
KATP Channels
Similarly to the GIRK channels, signaling of A1Rs to KATP channels was first discov-
ered in myocytes, soon followed by a study demonstrating that these channels also open
in response to adenosine in CA1 hippocampal neurons of the rat [111]. Glibenclamide,
a KATP channel blocker, suppressed the adenosine-induced hyperpolarization of these
neurons. A later study in neurons of the substantia nigra delivered further proof that these
channels are activated by the A1R: selective A1R agonists induced an outward K+ current
sensitive to tolbutamide, another KATP blocker, while a selective antagonist abolished these
effects [112]. KATP channels also belong to the Kir superfamily and conduct an inwardly
rectifying K+ current that is inhibited by intracellular ATP. These hetero-octamer channels
are composed of four Kir6 subunits (Kir6.1 or Kir6.2) and four sulfonylurea receptor (SUR)
subunits (SUR1 or SUR2), with the Kir6 subunits forming the pore while the SUR subunits
serve a regulatory role. Binding of ATP to the cytoplasmic domain of Kir6 subunits closes
the channel [113]. When ATP concentrations drop, the channels open and hyperpolarize
the cell membrane. This way, KATP channels generally respond to the metabolic activity of
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cells. However, the sensitivity to the ATP blockade can also be modulated by other proteins,
allowing KATP channels to open in response to external signals regardless of major changes
in ATP concentration. To date, the exact mechanism by which A1Rs modulate ATP gating
of these K+ channels remains unknown. Studies in cardiac myocytes point at a role for Gi/o
proteins as KATP channels could be activated by application of GTP-bound Gαi1-3 units
when the channels were closed by intracellular ATP [78,114,115]. In one of these studies,
the Gαo subunit was reported to have no effect [114], though in the other studies Gαo was
just as effective as the Gαi units [78,115]. At high concentration the Gβγ subunit could
also activate KATP channels, resulting in more potent effects compared to activation by
equimolar levels of Gα units [78]. In cardiac myocytes, adenosine activates KATP channels
through PLC-induced activation of PKC, which phosphorylates the Kir6.2 subunit resulting
in increased opening probability of the K+ channel [116,117]. In neurons it has yet to be
demonstrated that this signaling pathway plays a role in the A1R-mediated activation
of KATP channels but it is likely that G-protein dependent second messenger pathways
are also mediating KATP channel opening upon A1R activation. An increase in PLC/PKC
activity is thus likely to be involved in the modulation of neuronal KATP channels. However,
similar to GIRK channels, also inhibition of PLC activity by A1Rs (reported by some studies
in neurons, cfr. Section 5.2) can potentiate KATP channel function since PIP2 increases the
open probability of these channels [113]. Moreover, the AC/cAMP pathway could modu-
late neuronal KATP channels. One study has reported a cAMP-dependent modulation of
KATP channels by adenosine in breathing neurons of the pre-Bötzinger complex [118]. The
activity of these neurons displays a spontaneous respiratory rhythm, which is decreased
by A1R stimulation and an accompanying increase in KATP channel activity. The effects
of A1Rs on KATP channel and respiratory rhythm were neutralized by elevation of the
intracellular cAMP concentration. These results suggest that inhibition of cAMP formation
by A1Rs is involved in the activation of KATP channels, but so far this has not been studied
in any other neuronal cells.
Small Conductance Ca2+-Activated K+ Channels
In retinal ganglion cells, small conductance Ca2+-activated K+ (SK) channels are
mediating adenosine-evoked hyperpolarization next to GIRK channels [98]. Indeed, both a
GIRK channel blocker (rTertiapin-Q) and a SK channel blocker (apamin) partially inhibited
the outward current seen in whole-cell patch-clamp recordings. As their name implies,
small conductance Ca2+-activated K+ channels are activated by an increase in intracellular
calcium. Their high Ca2+ sensitivity is conferred by calmodulin, bound to the intracellular
C terminus of the SK channel. Binding of Ca2+ to calmodulin induces opening of the
channel, resulting in an outward K+ current [119]. The SK component of the A1R-induced
current in retinal ganglion cells was blocked by IP3 receptor antagonists [98]. This would
suggest that PLC-mediated formation of IP3 induces the release of Ca2+ from intracellular
stores, which activates the SK channels.
Two-Pore Domain K+ Channels
A recent study reported that the adenosine-mediated hyperpolarization of mitral
cells (projection neurons of the olfactory bulb) was partially blocked by two-pore domain
K+ (K2P) channel inhibitors (bupivacaine and halothane) [99]. This is a large family
of background K+ channels which stabilize the negative resting membrane potential.
A functional K2P channel consists of two subunits, each of which contains two pore
domains (hence the name). The activity of these channels is regulated by a wide variety of
parameters; some respond to changes in pH or temperature for example [120]. However,
some subfamilies of K2P channels are also known to be regulated by GPCRs. For instance,
stimulation of the PLC pathway by Gq-coupled receptors inhibits TASK (TWIK-related
acid-sensitive K+ channel) and TREK (TWIK-related K+ channel) subfamilies, but activates
channels of the TRESK (TWIK-related spinal cord K+ channel) subfamily. TREK channels
are also inhibited by an increase in cAMP, which is counteracted in case of Gi signaling [121].
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However, the specific subtype of the K2P channels that were activated by A1Rs in the study
on mitral cells could not be identified and thus the pathway responsible for their activation
is not known.
5.3.2. Suppression of Synaptic Transmission
Besides dampening neuronal excitation through opening of potassium channels,
presynaptic and postsynaptic A1Rs also antagonize excitation by directly modulating the
synaptic transmission (Figure 4). Presynaptically, A1R stimulation reduces the release of
glutamate and other neurotransmitters in a Ca2+-dependent and -independent manner.
Postsynaptically, A1R stimulation interferes with the function of NMDA (NMDARs) and
AMPA receptors (AMPARs), both ionotropic glutamate receptors mediating fast excitatory
neurotransmission.
Figure 4. Schematic representation of the signaling pathways involved in the suppression of neurotransmission by adenosine
A1 receptors (A1R). A1Rs suppress neurotransmitter release in a Ca2+-dependent way by inhibiting voltage-gated Ca2+
channels (VGCCs) via Gβγ. Additionally, VGCCs are inhibited through reduced PLC signaling resulting in reduced
disinhibition by PKC and increased inhibition by PIP2. Inhibition of PKA activity by A1R also enhances PIP2-mediated
inhibition of VGCCs. Through binding of Gβγ to SNARE proteins, A1Rs also suppress neurotransmitter release in a
Ca2+-independent way. Postsynaptic NMDA (NMDAR) and AMPA receptor (AMPAR) function is negatively modulated
by A1Rs through inhibition of PKA and PKC activity. AC: adenyl cyclase; cAMP: cyclic adenosine monophosphate; PKA:
protein kinase A; PLC: phospholipase C; PIP2: phosphatidylinositol 4,5-bisphosphate; IP3: inositol 1,4,5-trisphosphate;
DAG: diacylglycerol; PKC: phosphokinase C.
The following paragraphs of this section will focus on excitatory neurotransmission.
Nevertheless, it should be mentioned that A1Rs have also been found to reduce inhibitory
GABAergic transmission in several brain areas [122]. Such modulation of GABAergic
transmission could act as a complementary mechanism to control excitation of neuronal cir-
cuits. For instance, A1Rs have been demonstrated to suppress tonic GABAergic inhibition
of interneurons in the hippocampus [123]. Disinhibition of these interneurons results in
increased inhibition of pyramidal neurons, thus contributing to a decrease in hippocampal
network excitability [124].
Inhibition Ca2+-Dependent Neurotransmitter Release
Besides modulation of K+ channels, the effects of A1Rs on presynaptic Ca2+ chan-
nels are probably the best known explanation for the inhibitory/anticonvulsive effects of
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these receptors. Action potentials reaching the presynaptic terminal trigger opening of
voltage-gated Ca2+ channels (VGCCs) and the strong transient increase in intracellular Ca2+
nearby the VGCC (Ca2+ microdomains) triggers exocytosis of synaptic vesicles and neuro-
transmitter release [125]. Activation of A1Rs suppresses this evoked neurotransmission by
inhibiting the Ca2+ influx via VGCCs.
VGCCs are Ca2+ channels that open in response to large (high-voltage activated; HVA
channels) or small (low-voltage-activated; LVA channels) depolarizations of the membrane
potential. All VGCCs are composed of a pore-forming and voltage-sensitive α1 subunit,
consisting of four transmembrane domains. In case of HVA channels, the α1 subunit
co-assembles with ancillary α2δ and β subunits. LVA channels, on the other hand, function
as monomeric channels [126]. Based on differences in the α1 subunit, VGCCs are divided
over three families: Cav1, Cav2 and Cav3. The Cav3 family makes up the group of low
voltage-activated T-type Ca2+ channels, while Cav1 and Cav2 belong to the group of HVA
channels. The Cav1 family exists of four different types of L-type Ca2+ channels (Cav1.1-
1.4). The Cav2 family contains three members, each corresponding to a different type
of VGCC: the P/Q-type (Cav2.1), the N-type (Cav2.2) and the R-type (Cav2.3) channels.
The P/Q-type and the N-type channels are primarily responsible for the initiation of fast
synaptic transmission and therefore closely interact with proteins of the synaptic vesicle
release complex [126]. Specifically, these two VGCC types are inhibited by A1Rs.
Initial studies demonstrated reduced depolarization-evoked Ca2+ currents in the
soma of neurons. The authors of these studies suggested this might be the mecha-
nism for-adenosine-induced inhibition of neurotransmitter release if similar effects are
present at synaptic terminals [127–129]. Indeed, studies in hippocampal slices confirmed
that A1R agonists reduce presynaptic voltage-dependent Ca2+ currents at hippocampal
synapses [130,131]. Pretreatment withω-conotoxin GVIA (N-type VGCC blocker) attenu-
ated the effect of adenosine on Ca2+ currents in superior cervical ganglion neurons and
in hippocampal slices [129,131]. Interestingly, in these studies P/Q-type channels did not
seem to play an important role since pretreatment of the neuronal preparations with ω-
agatoxin IVA (P/Q-type VGCC blocker) did not result in any significant changes. However,
later studies revealed that P/Q-type channels are also modulated by A1Rs at hippocampal
synapses. The relative contribution of P/Q-type channels to an adenosine-induced de-
crease in Ca2+ current was similar to that of N-type channels at mossy fiber synapses [132].
Another study used ω-conotoxin MVIIC (another P/Q-type blocker) together with ω-
conotoxin GVIA in hippocampal synaptosomes to demonstrate the role of P/Q-type and
N-type channels [133]. When using a combination of both blockers, adenosine could even
further decrease the release of glutamate at hippocampal nerve terminals, suggesting
other non-identified VGCCs or other mechanisms (as will be discussed below) may also
be involved.
Early studies demonstrated that the activation of PTX-sensitive Gi/o proteins is essen-
tial for the effects of adenosine on VGCCs and neurotransmission. Activation of G-proteins
through the application of GTP-γS in chick sensory neurons mimicked adenosine-induced
inhibition of Ca2+ currents [128], while PTX-based inhibition of Gi proteins abolished the
inhibitory effects of adenosine on depolarization-induced Ca2+ currents in ganglion neu-
rons [129] and glutamate release by cerebellar neurons [134]. Selective expression of Gβγ
units mimicked the effects of Gi/o-coupled GPCRs on P/Q- and N-type channels indicating
that Gβγ is directly involved in the inhibition of Cav2 channels [135–137]. The α1 units
of these VGCCs indeed possess binding sites for Gβγ in the linker between domain I and
domain II that, together with the N-terminal region, form an important interaction site with
the Gβγ unit [138,139]. Binding of Gβγ to this interaction site stabilizes the closed confor-
mation of the VGCCs. This direct form of inhibition by G proteins is voltage-dependent as
strong membrane depolarization causes a brief dissociation of Gβγ from the channel [135].
Slower, voltage-independent regulation of VGCCs through G-protein mediated second
messenger pathways are also in play. The PLC pathway increases P/Q- and N-type
VGCC function through PKC-mediated phosphorylation of the domain I-II linker which
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antagonizes Gβγ-mediated inhibition of these VGCCs [138,140]. A1R-mediated inhibition
of the PLC/DAG/PKC pathway reduces this antagonism and supports reduced VGCC
activity. The activity of P/Q- and N-type channels is also modulated in two different
ways by PIP2 [141]. Firstly, binding of PIP2 to a presumable high-affinity site stabilizes
channel activity. Thus, depletion of PIP2 by PLC stimulation results in the closing of
VGCCs. Secondly, by binding to another, low-affinity binding site, PIP2 would cause the
VGCCs to be more reluctant to open, inhibiting currents evoked by small depolarizations.
Interestingly, this inhibition is blocked by phosphorylation by PKA. This could explain the
enhancement of P/Q- and N-type channel currents mediated by cAMP/PKA [142]. This
demonstrates that the AC/cAMP/PKA pathway also regulates VGCCs to some degree.
At this moment, it is unclear to which degree the PLC/DAG/PKC and AC/cAMP/PKA
pathways contribute to A1R-mediated inhibition of P/Q- and N-type channels. Two early
studies could not demonstrate a role of the cAMP/PKA pathway in A1R mediated in-
hibition of VGCC in chick sensory neurons and mossy fibers [128,132]. Modulation of
PKC activity did also not alter the effects of adenosine on Ca2+ currents in chick sen-
sory neurons [128]. In entorhinal cortex (EC) slices, adenosine-mediated suppression
of glutamatergic transmission is reduced after pretreatment with AC or PKA inhibitors,
suggesting a significant contribution of AC and PKA inhibition to adenosine-induced
suppression [143].
Decrease in Spontaneous Neurotransmitter Release
A1R signaling also suppresses neurotransmission in a calcium-independent way.
When synaptic vesicles spontaneously fuse with the presynaptic membrane, they release
small amounts of neurotransmitter which results in miniature postsynaptic currents (mP-
SCs). In hippocampal slices and cultured hippocampal neurons, the frequency of mPSCs
is reduced by applying A1R agonists. This inhibition is not affected by Ca2+ blockers,
indicating that A1Rs inhibit some component involved in vesicle release downstream from
Ca2 entry [144,145].
Although phosphorylation of proteins of the vesicle release complex by PKA and PKC
is known to play a role in Ca2+-independent regulation of neurotransmission, modulation
of the AC or PLC pathways does not seem to be involved in the inhibition of mPSCs by
adenosine [146,147]. For several other Gi/o-coupled GPCRs a crucial role for the Gβγ
subunit in inhibiting mPSCs has been demonstrated [148]. For example, the injection of
Gβγ in presynaptic terminals mimicked the inhibition of neurotransmission by serotonin
without affecting Ca2+ influx and when a Gβγ inhibitor was injected the inhibitory action
of serotonin was lost [149]. Through further investigation, it has been established that
Gβγ subunits directly interact with and most likely block SNARE complex proteins which
regulate fusion between synaptic vesicles and the synaptic membrane, thus inhibiting
exocytosis [148].
Inhibition NMDAR Currents
In hippocampal pyramidal cells [150] and basolateral amygdala neurons [151], whole-
cell patch-clamp recordings have shown that NMDAR-mediated currents are inhibited
by application of A1R agonists. NMDA (N-methyl-D-aspartate) receptors are ionotropic
glutamate receptors which exist as tetrameric channels composed of two GluN1 subunits
along with two GluN2 or GluN3 subunits [152]. Receptor activation does not only require
binding of glutamate, but also glycine binding and membrane depolarization for relief of
the Mg2+ block. Opening of the channel allows influx of cations, including Ca2+ due to a
high Ca2+ permeability. Ca2+ entry through NMDARs can initiate signaling cascades that
lead to modulation of synaptic strength. This way, NMDARs not only mediate synaptic
transmission but also synaptic plasticity [152]. In case of neuronal hyperactivity, however,
excessive NMDAR stimulation can lead to maladaptive synaptic changes or to cell death
due to extreme Ca2+ influx. By their inhibitory effect on NMDARs, A1R activation can
prevent those deleterious Ca2+-mediated effects on top of reducing depolarizing currents.
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NMDAR function is regulated by many postsynaptic GPCRs in a complex manner.
For several of those GPCRs, such as dopamine receptors or GABA receptors, the molecular
mechanisms behind the modulation have been well studied, showing that the signaling
pathways involved are very variable between the different GPCRs [153]. Even receptors
that couple to the same class of G proteins can have different effects on NMDAR activity;
Gαi coupled receptors for example may potentiate or depress NMDAR function [154]. Re-
garding adenosine receptors, more is known about regulation via A2ARs, which have been
reported to be able to both potentiate and inhibit NMDARs dependent on the cell type [153].
Though there is currently no direct evidence on the signaling pathways through which
A1Rs inhibit NMDAR function, literature provides some indications. Firstly, PKA-induced
phosphorylation of the C-terminal domains of GluN1 and GluN2 subunits increases NM-
DAR currents while blocking PKA activity decreases gating and Ca2+ permeability of
NMDARs [155,156]. A1R-mediated inhibition of the AC/cAMP/PKA cascade could thus
be responsible for the decrease in NMDAR currents. Secondly, PKC activity increases
opening of NMDARs, reduces the Mg2+ block and increases channel expression at the cell
surface via upregulation of SNARE-dependent exocytosis [157,158]. Therefore, in cells
where A1R activation inhibits the PLC/DAG/PKC cascade, it is also likely to result in
decreased NMDAR activity.
AMPAR Modulation
Modulation of AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors
by the A1R has received less attention compared to NMDARs, even though AMPARs
predominantly mediate fast excitatory transmission and antagonizing them results in more
potent seizure suppression [159]. AMPARs are ionotropic glutamate receptors formed
as tetramers from GluA1, GluA2, GluA3 or GluA4 subunits. Unlike NMDARs, most
AMPARs are only permeable to Na+ and K+ ions and not to Ca2+. They only require
binding of glutamate to open and cause depolarization of the membrane potential. While
NMDARs possess a relatively stable expression at synapses, AMPARs are more dynamically
expressed and can move into or out of the postsynaptic membrane. This variability in
AMPAR expression levels is an important factor in the regulation of synaptic plasticity and
is mediated by the Ca2+ influx caused by NMDARs [159].
A1Rs also modulate AMPAR trafficking independent from their effect on NMDARs.
The phosphorylation of certain serine and threonine residues at the C-terminus of AMPAR
subunits by several kinases, including PKA and PKC, plays an important role in AMPAR
function and trafficking [160]. Especially PKA-mediated phosphorylation of Ser845 in
GluA1 is key in AMPAR regulation. A1Rs maintain an inhibitory tone on Ser845 phospho-
rylation by inhibiting AC in several regions of the rat brain. Inhibition of A1R signaling
under basal adenosine concentrations increases Ser845 phosphorylation and potentiates
AMPAR currents while selective A1R activation reduces AMPAR currents in hippocampal
slices [161,162]. Furthermore, it was also reported that A1Rs decrease the agonist affinity
of AMPARs [162].
In addition, A1Rs can also reduce AMPAR expression through protein phosphatases
(PP) which dephosphorylate the serine residues involved in receptor trafficking. A study
in rat hippocampal slices demonstrated that GluA1 and GluA2 internalization after pro-
longed A1R stimulation is mediated by PP1, PP2A and PP2B using selective phosphatase
inhibitors [163]. The signaling pathway for activation of phosphatases by A1Rs possibly
involves mitogen-activated protein kinases (MAPKs) since PP2A is activated by p38 MAPK
upon A1R stimulation [164,165] and inhibition of p38 MAPK and JNK (c-Jun N-terminal
kinase) prevents GluA2 subunit internalization [166]. This signaling pathway will be
discussed in more detail in the following section.
5.4. Other Signaling Pathways and Their Effects
The effects discussed above are the most well-known and major mechanisms by which
the A1R leads to neuronal inhibition and anticonvulsant effects. They immediately affect
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neuronal excitability and are all mediated by the AC or PLC pathway and/or directly by
G protein subunits. However, activation of A1Rs can result in several additional effects
through activation of a variety of other signaling pathways. Below, we will outline a couple
of other important pathways affected by the A1R, together with their relevance in the
context of epilepsy.
5.4.1. Activation of MAP Kinases
MAP kinases are a protein family consisting of three main groups: the extracellu-
lar signal-regulated kinases (ERKs), the c-Jun N-terminal kinases (JNKs) and the p38
MAPKs/stress-activated protein kinases (SAPKs) [167]. These kinases are well known for
their role in cell proliferation, cell growth and cell death, but they are involved in many
more cellular functions. MAPKs are activated by various extracellular stimuli through a
cascade of protein kinases; the MAPK kinases (MAPKK) and the MAPKK kinases (MAP-
KKK). The canonical pathway for activating MAPKs involves binding of mitogens (hence
the name) or growth factors to receptor tyrosine kinases, followed by receptor dimerization
and cross-autophosphorylation. This receptor phosphorylation triggers a signaling cascade
via various intermediate proteins upstream from the MAPKKK.
GPCRs, including all adenosine receptors, can also activate MAPKs by tapping into
this pathway [168]. All three groups of MAPKs are activated by A1Rs (Figure 5) [169,170],
of which A1R-mediated activation of ERKs is best studied. It was first discovered in
immortalized kidney fibroblasts (COS-7 cells) that ERK1 is activated by A1Rs (and other
Gi-coupled receptors) via Gβγ subunits [171]. Further studies in CHO cells showed
that Gβγ activates tyrosine kinase which then phosphorylates Shc. Phosphorylated Shc
forms a complex with Grb2 followed by consecutive activation of Sos, Ras and c-Raf.
c-Raf is the MAPKKK that leads to ERK1/2 activation [172]. However, this pathway
cannot be generalized to all cell types since a study in a smooth muscle cell line showed
that tyrosine kinase inhibition did not block A1Rs-mediated activation of ERK1/2, but
phosphatidylinositol 3-kinase (PI3K) inhibitors did. [169]. PI3K could theoretically mediate
JNK and p38 MAPK activation as well. Phosphatidylinositol 3,4,5-trisphosphate (PIP3),
formed by PI3K, activates the guanine–nucleotide exchange factor Prex1 which in turn
activates Rac [173]. Rac is a GTPase is involved in signaling cascades leading to JNK and
p38 MAPK activation [174].
Activation of MAPK pathways by A1Rs most likely contributes to the seizure-suppressive
effects of adenosine. JNK and p38 MAPK are involved in A1R-mediated suppression
of synaptic transmission in the CA1 region of the hippocampus by mediating for ex-
ample AMPAR internalization via activation of phosphatases (see AMPAR Modulation,
Section 5.3.2) [166,175]. Furthermore, MAPKs are involved in protective mechanisms
against seizure-induced cell death. Acute seizures in rats induce ERK and p38 MAPK
activation in the hippocampus. Blocking these MAPKs aggravates neuronal degradation
caused by a subsequent status epilepticus [176]. However, excessive activation of MAPK
pathways can also cause negative effects. For instance, constitutive ERK activation increases
NMDAR activity by augmenting GluN2 subunit protein levels. This increases neuronal
excitability and results in epileptic seizures [177]. Additionally, MAPKs are implicated
in epileptogenesis by affecting RNA-binding proteins. In this way, the overactivation of
MAPKs can lead to aberrant expression of synaptic proteins [178]. Acute activation of
MAPKs by the A1R could thus be beneficial, but overactivation becomes more detrimental.
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Figure 5. Activation of MAPK pathways (highlighted in yellow), the guanyl cyclase pathway (highlighted in orange)
and nuclear factor-κB (highlighted in purple) by the adenosine A1 receptor (A1R). AC: adenyl cyclase; cAMP: cyclic
adenosine monophosphate; PKA: protein kinase A; PLC: phospholipase C; PIP2: phosphatidylinositol 4,5-bisphosphate;
IP3: inositol 1,4,5-trisphosphate; DAG: diacylglycerol; PKC: phosphokinase C; CamKII: calmodulin-dependent protein
kinase II; PI3K: phosphatidylinositol 3-kinase; PIP3: phosphatidylinositol 3,4,5-trisphosphate; JNK: c-Jun N-terminal kinase;
ERK: extracellular signal-regulated kinase; p38 MAPK: p38 mitogen-activated protein kinase; NOS: nitric oxide synthase;
NO: nitric oxide; sGC: soluble guanylyl cyclase; cGMP: cyclic guanosine monophosphate; PKG: protein kinase G; IKK: IκB
kinase; NF-kB: nuclear factor-κB.
5.4.2. Guanyl Cyclase Pathway
Another pathway activated by the A1R is the soluble guanylyl cyclase (sGC) or the
nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) pathway. Nitric oxide release
upon activation of nitric oxide synthase (NOS) activates sGC, which converts GTP to
cGMP. The main effector of cGMP is protein kinase G (PKG). In the CNS, the NO/cGMP
pathway exerts many functions including modulation of neuronal excitability and synaptic
transmission [179,180].
By blocking NOS, sGC and PKG, Cascalheira et al. demonstrated that A1R-induced
inhibition of neurotransmission in the CA1 region of hippocampal slices is partly mediated
by the NO/cGMP pathway [181,182]. In cardiomyocytes, the activation of A1Rs stimulates
NOS through activation of PLC and subsequent increase in Ca2+/calmodulin and PKC
activity [183]. Moreover, the A1R-induced phosphorylation of p38 MAPK is prevented by
inhibitors of the cGMP pathway, providing a link between A1R—induced activation of
NO/cGMP and MAPKs [165]. It is yet to be determined whether these mechanisms apply
to neurons as well.
5.4.3. Modulation of Nuclear Factor-κB and Brain-Derived Neurotrophic Factor
Stimulation of A1Rs can also produce more delayed effects by influencing gene expres-
sion. As an example, we will briefly discuss the effects of the A1R on the transcription factor
nuclear factor-κB (NF-κB) and one of its target gene products—brain-derived neurotrophic
factor (BDNF)—since these factors are involved in epilepsy.
NF-κB is an inducible transcription factor that regulates the expression of hundreds of
genes involved in inflammation, immunity, cell survival and cell differentiation. NF-κB is
present in the cytoplasm in an inactive state as long as it is associated with its inhibitor;
IκB (inhibitor of κB). Phosphorylation of IκB triggers its ubiquitination and degradation
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and activation of NF-κB [184]. NF-κB activation can be initiated by a large number of
environmental stimuli, such as bacterial products or UV light, as well as by a variety
of GPCRs, including the A1R. It was shown, for example, that application of adenosine
in rat basal forebrain slices increased the amount of NF-κB bound to DNA. This was
significantly reduced by pretreatment of the slices with an A1R antagonist [185]. On a
side note, NF-κB can also bind to the promoter sequence of the A1R gene and increase
A1R expression [186]. The signaling pathway responsible for the activation of NF-κB by
A1Rs is not yet clarified. In human lymphoblastoma and embryonic kidney cells [187],
A1R-induced NF-κB activation was not mediated by Gi/o proteins but instead relied on
G16, a G protein specific to hematopoietic cells [188]. Two cascades were found to be
initiated by Gα16 and Gβγ: (1) activation of PLC, resulting in activation of PKC and
calmodulin-dependent protein kinase II (CaMKII) due to increased Ca2+ concentration
and (2) activation of the tyrosine kinase c-Src, which initiates a MAPK cascade leading
to phosphorylation of ERK via Ras and c-Raf. All three kinases -PKC, CaMKII and ERK-
can activate the IκB kinase (IKK) complex which phosphorylates IκB and releases NF-κB.
Whether any of these pathways are involved in NF-κB activation in neurons remains to
be studied.
In the CNS, NF-κB can have a neuroprotective role, but it is also involved in neu-
rodegeneration. It is believed that a certain level of NF-κB is required to maintain normal
neuronal functioning while too low or too high NF-κB levels are pathological [189]. Based
on preclinical seizure models, it is not clear whether the activation of NF-κB by A1Rs could
be beneficial or detrimental. In one rat study, inhibition of NF-κB increased susceptibility
for kainic acid induced seizures [190]. However, another study in the same rat model
showed a decrease in seizure susceptibility and also found that NF-κB inhibition resulted
in decreased expression of P-glycoprotein [191]. NF-κB activation could thus lead to an
elevated risk for seizures and increased P-glycoprotein expression, an important multidrug
transporter implicated in drug-resistance in epilepsy. These conflicting results demonstrate
the complexity of NF-κB signaling, owing to the many possible genes that can be induced
by this transcription factor.
One of the genes which expression is affected by NF-κB is BDNF [192]. Induction of
NF-κB activity in response to kainic acid administration increases the expression of BDNF
both in vitro as in vivo [190,193]. A1R stimulation could thus result in upregulation of
BDNF via NF-κB. This is supported by a recent study with A1R-knock out mice, where
BDNF levels after seizure induction were lower in the knock out compared to wild type
animals [194]. As neurotrophin, BDNF is important for the growth and survival of neurons
during development. In the mature brain, the function of BDNF is less clear. BDNF has been
reported to induce phosphorylation of GluN1 subunits of NMDARs, thereby increasing
their activity [195]. In the context of epilepsy, indeed, most evidence indicates that BDNF
increases neuronal excitability and contributes to epileptogenesis [196,197]. However, there
is some evidence that BDNF can have a neuroprotective effect by increasing the expression
of the inhibitory neuropeptide Y (NPY) [196,197]. Via its Gi/o-coupled receptors, NPY also
inhibits several types of VGCCs and activates GIRK channels [198,199].
6. Conclusions
The importance of the A1R, through which the adenosinergic system exerts many of
its anticonvulsive and neuroprotective effects, is well established. This review provided an
overview of signaling pathways through which A1R activation yields those effects. The
two principal inhibitory neuronal mechanisms of the A1R are well known; (1) membrane
hyperpolarization caused by the activation of K+ channels and (2) suppression of synaptic
transmission via inhibition of VGCCs and synaptic vesicle release (Figure 6). The second
messenger systems and molecular mechanisms responsible for the activation or inhibition
of these targets, however, remain to be completely unraveled, though evidence indicates
important roles of the AC and the PLC pathways, along with the Gβγ subunit. Additional
evidence indicates a role for the NO/cGMP pathway and the MAPKs in mediating the
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inhibitory actions of the A1R. Caution must be taken, however, as a major part of the
evidence reviewed regarding A1R signaling is derived from studies in non-neuronal cells.
Beyond acute anticonvulsive effects, it is important to consider that A1R activation can
result in additional delayed and long-term neuromodulatory effects. These can have
an opposite, detrimental effect and potentially aggravate seizure activity. Thus, when
developing future epilepsy therapies based on A1R stimulation, the aim should be to evoke
the immediate inhibitory effects of the A1R while avoiding the negative effects of chronic
overstimulation.
Figure 6. Overview of the pre- and postsynaptic targets of the adenosine A1 receptor (A1R) through
which it mediates its main inhibitory neuromodulatory effects; hyperpolarization via activation of
K+ channels and suppression of synaptic transmission via inhibition of voltage-gated Ca2+ channels
(VGCCs) and proteins involved in exocytosis. AMPAR: AMPA receptor; NMDAR: NMDA receptor;
GIRK: G protein-coupled inwardly rectifying K+ channel; KATP: ATP-sensitive K+ channel; SK: small
conductance Ca2+-activated K+ channel; K2P: two-pore domain K+ channel.
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Abbreviations
A1R Adenosine A1 receptor
A2AR Adenosine A2A receptor
A2BR Adenosine A2B receptor





AMPAR A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor
ATP Adenosine triphosphate
BDNF Brain-derived neurotrophic factor
CamKII Calmoduline-dependent protein kinase II
cAMP Cyclic adenosine monophosphate
cGMP Cyclic guanosine monophosphate
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CHO Chinese hamster ovary
CNS Central nervous system
CREB cAMP response binding protein
DAG Diacylglycerol
ENT Equilibrative nucleoside transporter
ERK Extracellular signal-regulated kinase
FRET Fluorescence resonance energy transfer
Gα G protein α subunit
Gβγ G protein βγ subunit
GDP Guanosine diphosphate
GIRK G protein-coupled inwardly rectifying K+ channel




IκB Inhibitor of IκB
IP3 1,4,5-triphosphate
JNK c-Jun N-terminal kinase
K2P Two-pore domain K+ channel
KATP ATP-sensitive K+ channel
LVA Low-voltage activated
MAPK Mitogen-activated protein kinase
MAPKK MAPK kinase
MAPKKK MAPKK kinase
mPSC Miniature postsynaptic current
NF-κB Nuclear factor-κB
NMDAR N-methyl D-aspartate receptor
NO Nitric oxide





PKA Protein kinase A
PKC Protein kinase C




SAPK Stress-activated protein kinase
sGC Soluble guanylyl cyclase
SK Small conductance Ca2+-activated K+ channel
SUR Sulfonylurea receptor
TASK TWIK-related acid sensitive K+ channel
TREK TWIK-related K+ channel
TRESK TWIK-related spinal cord K+ channel
VGCC Voltage-gated Ca2+ channel
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